1. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors
- Author
-
Qing Ming Wu, Xianlin Han, Cheng Zhi Gao, Wei Dong, Zhi-wen Cui, Qiong Yuan, Xia Min Hu, Yao Xu, and Zhen Li Min
- Subjects
Poly ADP ribose polymerase ,Poly (ADP-Ribose) Polymerase-1 ,Antineoplastic Agents ,Alzheimer's Disease ,01 natural sciences ,Molecular Docking Simulation ,Piperazines ,Olaparib ,chemistry.chemical_compound ,Structure-Activity Relationship ,Cell Line, Tumor ,Drug Discovery ,BChE ,Structure–activity relationship ,Animals ,Humans ,Horses ,Butyrylcholinesterase ,Cell Proliferation ,Pharmacology ,chemistry.chemical_classification ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Cell growth ,lcsh:RM1-950 ,General Medicine ,PARP-1 inhibitor ,In vitro ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,lcsh:Therapeutics. Pharmacology ,Enzyme ,Biochemistry ,Electrophorus ,Acetylcholinesterase ,AChE ,Phthalazines ,Cholinesterase Inhibitors ,Drug Screening Assays, Antitumor ,Research Paper - Abstract
A series of new Olaparib derivatives was designed and synthesized, and their inhibitory activities against poly (ADP-ribose) polymerases-1 (PARP-1) enzyme and cancer cell line MDA-MB-436 in vitro were evaluated. The results showed that compound 5l exhibited the most potent inhibitory effects on PARP-1 enzyme (16.10 ± 1.25 nM) and MDA-MB-436 cancer cell (11.62 ± 2.15 μM), which was close to that of Olaparib. As a PARP-1 inhibitor had been reported to be viable to neuroprotection, in order to search for new multitarget-directed ligands (MTDLs) for the treatment of Alzheimer’s disease (AD), the inhibitory activities of the synthesized compounds against the enzymes AChE (from electric eel) and BChE (from equine serum) were also tested. Compound 5l displayed moderate BChE inhibitory activity (9.16 ± 0.91 μM) which was stronger than neostigmine (12.01 ± 0.45 μM) and exhibited selectivity for BChE over AChE to some degree. Molecular docking studies indicated that 5l could bind simultaneously to the catalytic active of PARP-1, but it could not interact well with huBChE. For pursuit of PARP-1 and BChE dual-targeted inhibitors against AD, small and flexible non-polar groups introduced to the compound seemed to be conducive to improving its inhibitory potency on huBChE, while keeping phthalazine-1-one moiety unchanged which was mainly responsible for PARP-1 inhibitory activity. Our research gave a clue to search for new agents based on AChE and PARP-1 dual-inhibited activities to treat Alzheimer’s disease.
- Published
- 2018